LASSBio-1359 reduces pain and inflammation in an animal model

This study investigated the antinociceptive action of (E)-N'-(3,4-Dimethoxybenzylidene)-N-methylbenzohydrazide (LASSBio-1359) in acute and chronic inflammatory pain in mice. The reactivity to formalin in mice evaluated and LASSBio-1359 at doses of 10 and 20 mg/kg intraperitoneally (i.p.) improved the response in the neurogenic and inflammatory phase. The antinociceptive action of LASSBio-1359 was not seen with the pre-treatment with yohimbine and/ or ZM241385, respectively. LASSBio-1359 showed central antinociceptive activity that was reversed by yohimbine. The carrageenan (1%) induced thermal and mechanical hyperalgesia that was enhanced after treatment with LASSBio-1359. Complete Freund's adjuvant (CFA) used for monoarthritis induction that reduced the paw withdrawal threshold after thermal and mechanical stimulation. However, the oral administration of LASSBio-1359 improved from hyperalgesia caused by CFA, normalized TNF- and iNOS expression in the paws and did not show central toxicity indicating that it could be a new alternative for the treatment of nociception and inflammatory caused by monoarthritis.

Autorentext

Guilherme Carneiro Montes has a solid experience in the pharmacology and drug development area. Currently, he works as Basic and Clinical Pharmacology Professor at Universidade Estadual do Rio de Janeiro. He has a Pharmacy degree (BSc), PhD in Pharmacology and Medicinal Chemestry (ICB/UFRJ).Research areas in Pharmacology of pain, inflammation

Klappentext

This study investigated the antinociceptive action of (E)-N -(3,4-Dimethoxybenzylidene)-N-methylbenzohydrazide (LASSBio-1359) in acute and chronic inflammatory pain in mice. The reactivity to formalin in mice evaluated and LASSBio-1359 at doses of 10 and 20 mg/kg intraperitoneally (i.p.) improved the response in the neurogenic and inflammatory phase. The antinociceptive action of LASSBio-1359 was not seen with the pre-treatment with yohimbine and/ or ZM241385, respectively. LASSBio-1359 showed central antinociceptive activity that was reversed by yohimbine. The carrageenan (1%) induced thermal and mechanical hyperalgesia that was enhanced after treatment with LASSBio-1359. Complete Freund's adjuvant (CFA) used for monoarthritis induction that reduced the paw withdrawal threshold after thermal and mechanical stimulation. However, the oral administration of LASSBio-1359 improved from hyperalgesia caused by CFA, normalized TNF- and iNOS expression in the paws and did not show central toxicity indicating that it could be a new alternative for the treatment of nociception and inflammatory caused by monoarthritis.